نبذة مختصرة : The resistance mechanism of osimertinib, a third-generation EGFR-TKI, is mediated by IL-6 and Laminin α5/FAK signaling. Ibrutinib combined with osimertinib is presented as a strategy for overcoming osimertinib acquired resistance in EGFR mutant NSCLC.
No Comments.